Evidence map›Paper›PMID 40400470›Full record

ArticleHaematologica2025

Clonal plasma cell features in light chain amyloidosis are associated with depth and timing of cardiac response independent of hematologic response.

Matthew J Rees, Susan Geyer, Binoy Yohannan, Nadia Toumeh, Suheil Albert Atallah-Yunes, Morie A Gertz, Angela Dispenzieri, Suzanne R Hayman, Francis Buadi, David Dingli and 11 more

Abstract read
In one paragraph

Article in Haematologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Matthew J ReesDivision of Hematology, Mayo Clinic, Rochester, MN. Rees.Matthew@mayo.edu.
Susan GeyerDivision of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN.
Binoy YohannanDivision of Hematology, Mayo Clinic, Rochester, MN.
Nadia ToumehDivision of Hematology, Mayo Clinic, Rochester, MN.
Suheil Albert Atallah-YunesDivision of Hematology, Mayo Clinic, Rochester, MN.
Morie A GertzDivision of Hematology, Mayo Clinic, Rochester, MN.
Angela DispenzieriDivision of Hematology, Mayo Clinic, Rochester, MN.
Suzanne R HaymanDivision of Hematology, Mayo Clinic, Rochester, MN.
Francis BuadiDivision of Hematology, Mayo Clinic, Rochester, MN.
David DingliDivision of Hematology, Mayo Clinic, Rochester, MN.
Rahma WarsameDivision of Hematology, Mayo Clinic, Rochester, MN.
Prashant KapoorDivision of Hematology, Mayo Clinic, Rochester, MN.
Martha GroganDivision of Cardiology, Mayo Clinic, Rochester, MN.
Joselle CookDivision of Hematology, Mayo Clinic, Rochester, MN.
Moritz BinderDivision of Hematology, Mayo Clinic, Rochester, MN.
Nelson LeungDivision of Hematology, Mayo Clinic, Rochester, MN.
Taxiarchis KourelisDivision of Hematology, Mayo Clinic, Rochester, MN.
Wilson GonsalvesDivision of Hematology, Mayo Clinic, Rochester, MN.
Vincent S RajkumarDivision of Hematology, Mayo Clinic, Rochester, MN.
Shaji KumarDivision of Hematology, Mayo Clinic, Rochester, MN.
Eli MuchtarDivision of Hematology, Mayo Clinic, Rochester, MN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiac response is associated with survival in AL amyloidosis, but substantial variation exists in response kinetics. We investigated variables associated with deep cardiac responses to characterize the factors that govern organ recovery. We retrospectively studied newly diagnosed AL amyloidosis patients (N=401) diagnosed between 2010-2022 in whom cardiac response could be assessed. Cardiac responses were recorded at 6, 12 and 24 months and the best cardiac response. A deep cardiac response was defined as a cardiac very good partial response or better (>60% reduction in baseline N-terminal pro-B-type natriuretic peptide or ≤350 pg/mL). High-risk cytogenetic abnormalities (HRCA) included del(17p), t (4;14), t(14;16), and t(14;20). Logistic and competing-risk regression analyses (treating death as a competing event) were used to examine variables associated with cardiac response. The median age of the patients was 65 years, and their median follow- up was 5.5 years. At the 6-, 12- and 24-month and best overall response landmarks, 12%, 24%, 33% and 45%, respectively, of patients had obtained a cardiac very good partial response or better. Having baseline bone marrow plasma cells (BMPC) ≥20%, obtaining a hematologic very good partial response or better within 6 months, having a κ isotype, having HRCA and undergoing autologous stem cell transplantation (ASCT) were significantly associated with deep cardiac response on logistic regression and competing-risk analysis. In line with their impact on cardiac response, ASCT, κ isotype and deep hematologic response within 6 months were associated with improved overall survival on multivariable Cox proportional hazards modeling. Conversely, high BMPC burden and the presence of HRCA had no association with overall survival on adjusted analysis. As this cohort was retrospectively selected for cardiac response assessment, these results need to be interpreted accordingly. Nonetheless, the association between a 'myeloma phenotype' and cardiac response kinetics, endorses the role of direct light chain toxicity and suggests that clonal plasma cell features significantly influence organ response in AL amyloidosis.

Indexed as

Immunoglobulin Light-chain AmyloidosisPlasma CellsAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedRetrospective Studies

Identifiers

PMID40400470
PMCPMC12580697

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.